Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: A randomised controlled trial.

ABSTRACT:

Background

Melatonin may reduce REM-sleep behavior disorder (RBD) symptoms in Parkinson's disease (PD), though robust clinical trials are lacking.

Objective

To assess the efficacy of prolonged-release (PR) melatonin for RBD in PD.

Methods

Randomized, double-blind, placebo-controlled, parallel-group trial with an 8-week intervention and 4-week observation pre- and postintervention (ACTRN12613000648729). Thirty PD patients with rapid eye movement sleep behavior disorder were randomized to 4 mg of prolonged-release melatonin (Circadin) or matched placebo, ingested orally once-daily before bedtime. Primary outcome was the aggregate of rapid eye movement sleep behavior disorder incidents averaged over weeks 5 to 8 of treatment captured by a weekly diary. Data were included

SUBMITTER: Gilat M 

PROVIDER: S-EPMC7027846 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature